Built In Honors Q2 with 2023 Best Places to Work Award
Q2 earns local and national placements on Built In’s Best Places to Work List AUSTIN,…
Year: 2023
The Year of the Cost-Conscious Consumer: Similarweb Estimates 100 Fastest-Growing Digital Brands of 2022
Appeals to consumer frugality drove growth across many domains NEW YORK–(BUSINESS WIRE)–With its annual Digital…
Ground Labs Introduces Enterprise Recon 2.8 with New Way of Discovering Critical Data in Microsoft Platforms
Award-winning data discovery solution scans and remediates widest number and range of data types in…
Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule
LAVAL, Québec, Jan. 25, 2023 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”)…
Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors
Nes-Ziona, Israel, Jan. 25, 2023 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”),…
Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
Preclinical Efficacy and Safety Results Indicate AlloCAR T™ Development Candidate Controls Tumor Growth without Off-Tumor/Normal Tissue…
AnPac Bio-Medical Science Announces Signing of US$5.2 Million of Definitive Investment Agreements
New York, NY, Jan. 25, 2023 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (the “Company”)…
SciSparc Announces Corporate Restructuring plan
SciSparc will examine the possibility of a public listing for its pharmaceutical activity while retaining…
Hebrew University’ Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023
Isranalytica 2023, the Annual meeting of the Israel Analytical Chemical Society, provided Clearmind with the…
Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor
– Dr. De Backer to assume CEO role on April 3, 2023 – – Upon…
Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII
Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for…
Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX),…
Precision Neuroscience Raises $41 Million to Build and Scale the Next Generation of Treatments for Neurological Illnesses
The brain–computer interface company advances the industry with plans for a minimally invasive, reversible implant….
Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing Tumors
First Immunosynthen ADC product candidate enters the clinic CAMBRIDGE, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE)…
Grace Breeding Study Results of its Proprietary Environment- Friendly Bio-Fertilizer (“NFT”) Show Superior Growth Results in Brazilian Corn, Outperforming Standard Nitrogen Fertilizers While Reducing Carbon Emissions
Final study results show Grace Breeding’s NFT, an alternative to reduce urea, was superior or…
Eloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome
Topline results expected in first half of 2023 Trial sites open in Australia and United…
Jasper Therapeutics Announces Pricing of $90 Million Public Offering of Common Stock
REDWOOD CITY, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”),…
Capricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients
-Statistically Significant Results in Performance of the Upper Limb PUL 2.0 (p=0.02) Extended to 18…
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi
Partner Sanofi has commenced dosing in a Phase 2 clinical trial of SAR443820 (DNL788) in…
Oncotelic Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic Cancer
AGOURA HILLS, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc (OTCQB:OTLC) (“Oncotelic”, the…